BioSpace News Archive

Salarius Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced that it will host a virtual key opinion leader and investor event focused on the scientific rationale and clinical development of seclidemstat, the Company’s lead drug candidate.

Gritstone bio, Inc. today announced that the Compensation Committee of the company’s Board of Directors has granted five employees nonqualified stock options.

Metacrine, Inc. today announced that it will present data at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2021, being held virtually from June 23-26, 2021.

Qpex Biopharma, Inc. announced initiation of a Phase 1 study of QPX9003, a next generation intravenous (IV)-administered synthetic polymyxin for infections.

Lineage Announces Exclusive Option Agreement With Amasa Therapeutics for Supply and Use of Clinical-Grade Hystem,

Amneal Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for Bevacizumab.

Aerie Pharmaceuticals, Inc. announced the completion of patient enrollment for its first Phase 3 clinical trial of netarsudil ophthalmic solution in Japan, comparing netarsudil ophthalmic solution 0.02%, administered once a day in the evening, to ripasudil hydrochloride hydrate ophthalmic solution 0.4%, marketed as Glanatec® in Japan, administered twice a day, in the morning and evening.

FibroGen, Inc. and HiFiBiO Therapeutics, a private, multinational clinical-stage biotherapeutics company with expertise in immune modulation and single cell science announced a partnership covering three HiFiBiO programs.

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced that the U.S. Food and Drug Administration has granted Fast Track designation to AT-007 for the treatment of Galactosemia, a rare metabolic disease.

OPKO Health, Inc. announces that its subsidiary, EirGen Pharma, Ltd., has entered into a definitive agreement to sell one of its facilities in Waterford, Ireland to Horizon Therapeutics plc for $65 million in cash less certain assumed and accrued liabilities relating to transferred employees.